BostonGene to Present Multimodal AI Advances in Oncology at ESMO Congress
BostonGene, an AI model developer for tumor and immune biology, will present its advancements in multimodal AI at the ESMO AI & Digital Oncology Congress 2026 in Berlin, Germany. The company will showcase how its AI platform addresses critical oncology challenges, including accurately identifying tumor origin in cancers of unknown primary (CUP) and deconvolving complex transcriptomic data. BostonGene has clinically validated its proprietary multimodal AI framework, developed in collaboration with researchers at Weill Cornell Medicine, to classify tumor origin from incomplete clinical data. This framework integrates histopathology, transcriptomics, and genomics, demonstrating accurate prediction even from partial diagnostic profiles. Additionally, BostonGene developed a pan-cancer deep learning platform that dissects bulk RNA-seq data across 20 tumor microenvironment cell types and 13 tumor diagnoses, yielding over 14,000 compartment-specific gene expression profiles. This platform, evaluated in collaborati...